

---

**Meeting of the WHO Product Development for Vaccines Advisory Committee (PDVAC)**  
**Virtual session on HIV monoclonal antibodies, 15 April 2021**

<b>PDVAC COMMITTEE MEMBERS</b>
--------------------------------

**Klaus Cichutek** (*apologies*)

Paul-Ehrlich-Institute (PEI)  
Langen, Germany

[klaus.cichutek@pei.de](mailto:klaus.cichutek@pei.de)

**Sinead Delany-Moretlwe**

University of Witwatersrand (Wits)  
Johannesburg, South Africa

[sdelany@wrhi.ac.za](mailto:sdelany@wrhi.ac.za)

**Bernard Fritzell**

Independent  
Bordeaux, France

[bernardfritzell@hotmail.fr](mailto:bernardfritzell@hotmail.fr)

**Barney Graham**

NIAID, Vaccine Research Center  
Bethesda, USA

[bgraham@mail.nih.gov](mailto:bgraham@mail.nih.gov)

**Gagandeep Kang**

Translational Health Science and Technology  
Institute (THSTI)  
Faridabad, India

[gkang@thsti.res.in](mailto:gkang@thsti.res.in)

**Ruth Karron**

Johns Hopkins Bloomberg School of Public Health  
(JHSPH)  
Baltimore, USA

[rkarron@jhsphe.edu](mailto:rkarron@jhsphe.edu)

**David Kaslow (CHAIR)**

PATH  
Seattle, USA

[dkaslow@path.org](mailto:dkaslow@path.org)

**Jerome Kim**

International Vaccine Institute (IVI)  
Seoul, Korea

[Jerome.Kim@ivi.int](mailto:Jerome.Kim@ivi.int)

**Claudio Lanata**

Instituto de Investigación Nutricional  
Lima, Peru

[clanata@iin.sld.pe](mailto:clanata@iin.sld.pe)

**Beno Y. Nyam**

National Agency for Food and Drug Administration and  
Control  
Lagos, Nigeria

[beno.y@nafdac.gov.ng](mailto:beno.y@nafdac.gov.ng)

**Yiming Shao**

Chinese Center for Disease Control and Prevention  
(CDC)  
Beijing, China

[yshao@bjmu.edu.cn](mailto:yshao@bjmu.edu.cn)

**Peter Smith**

London School of Hygiene and Tropical Medicine (LSHTM)  
London, UK

[Peter.Smith@lshtm.ac.uk](mailto:Peter.Smith@lshtm.ac.uk)

**Marian W. Wentworth**

Management Sciences for Health (MSH)  
Medford, USA

[mwentworth@msh.org](mailto:mwentworth@msh.org)

**NON- MEMBER PARTICIPANTS****Alejandro Cravioto**

University of Mexico  
Puerto Vallarta, Mexico

[dracravioto@hotmail.com](mailto:dracravioto@hotmail.com)

**Patricia Fast**

IAVI  
New York, USA

[PFast@iavi.org](mailto:PFast@iavi.org)

**Lucio Gama**

NIH,  
Bethesda, USA

[lucio.gama@nih.gov](mailto:lucio.gama@nih.gov)

**Shelly Malhotra**

IAVI  
New York, USA

[SMalhotra@iavi.org](mailto:SMalhotra@iavi.org)

**Deepali Patel**

Gavi, the Alliance  
Geneva, Switzerland

[dpatel@gavi.org](mailto:dpatel@gavi.org)

**Velislava Petrova**

Gavi, the Alliance  
Geneva, Switzerland

[vpetrova@gavi.org](mailto:vpetrova@gavi.org)

**Roger Tatoud**

International AIDS Society  
Geneva, Switzerland

[roger.tatoud@iasociety.org](mailto:roger.tatoud@iasociety.org)

**HIV mAbs and Vaccine Working Group****Susan Buchbinder**

Bridge HIV CRS  
San Francisco, USA

[susan.buchbinder@sfdph.org](mailto:susan.buchbinder@sfdph.org)

**Zvavahera (Mike) Chirenje**

University of Zimbabwe  
Harare, Zimbabwe

[mchirenje@uzchs-ctrc.org](mailto:mchirenje@uzchs-ctrc.org)

**Nelly Mugo**  
CDC Kisumu  
Nairobi, Kenya

[Rwamba@csrtenya.org](mailto:Rwamba@csrtenya.org)

**Mitchell Warren**  
AVAC  
New York, USA

[mitchell@avac.org](mailto:mitchell@avac.org)

<b>WHO HQ SECRETARIAT</b>
---------------------------

**Rachel Baggaley**, Technical Officer, Regulatory Systems Strengthening, HIS/EMP

**Martin Friede**, Unit Head, Vaccine Product & Delivery Research, UHL/IVB

**Birgitte Giersing**, Team Lead, Vaccine Prioritization and Platforms, UHL/IVB

**Michelle Rodoloph**, Coordinator, Testing, Prevention and Populations, UCN/HHS

**Erin Sparrow**, Technical Officer, Technical Officer, Vaccine Prioritization and Platforms UHL/IVB